Literature DB >> 16376151

ICAT-based comparative proteomic analysis of non-replicating persistent Mycobacterium tuberculosis.

Sang Hyun Cho1, David Goodlett, Scott Franzblau.   

Abstract

The non-replicating persistence (NRP) phenotype of Mycobacterium tuberculosis (NRP-TB) is assumed to be responsible for the maintenance of latent infection and the requirement of a long treatment duration for active tuberculosis. Isotope coded affinity tag-based proteomic analysis was used for the determination of the relative expression of large numbers of M. tuberculosis proteins during oxygen self-depletion under controlled conditions in a multi-chambered fermentor. Expression of the alpha-crystallin homolog protein, acr, was monitored and quantified to confirm entry into NRP. Relative expression of 586 and 628 proteins was determined in log phase vs. early stage NRP (NRP-1) and log phase vs. later stage NRP (NRP-2), respectively. Relative to expression in log phase and using an abundance ratio of +/-2.0 as a cutoff, 6.5% and 20.4% of proteins were found to be upregulated in NRP-1 and NRP-2, respectively while 20.3% and 13.4% were downregulated, respectively. Functional profiling revealed that 42.1%/39.8% of upregulated proteins and 41.2%/45.2% of downregulated proteins in NRP-1/NRP-2, respectively, were involved in small molecule metabolism. Among those proteins the highest proportions of 37.5% in NRP-1 were involved with degradation and of 45.1% in NRP-2 with energy metabolism. These results suggest distinct protein expression profiles in NRP-1 and NRP-2.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16376151     DOI: 10.1016/j.tube.2005.10.002

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  25 in total

1.  Metabolomics Studies To Decipher Stress Responses in Mycobacterium smegmatis Point to a Putative Pathway of Methylated Amine Biosynthesis.

Authors:  Arshad Rizvi; Saleem Yousf; Kannan Balakrishnan; Harish Kumar Dubey; Shekhar C Mande; Jeetender Chugh; Sharmistha Banerjee
Journal:  J Bacteriol       Date:  2019-07-10       Impact factor: 3.490

Review 2.  Natural products, small molecules, and genetics in tuberculosis drug development.

Authors:  Maria-Teresa Gutierrez-Lugo; Carole A Bewley
Journal:  J Med Chem       Date:  2008-04-05       Impact factor: 7.446

3.  Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.

Authors:  Sang Hyun Cho; Saradee Warit; Baojie Wan; Chang Hwa Hwang; Guido F Pauli; Scott G Franzblau
Journal:  Antimicrob Agents Chemother       Date:  2007-01-08       Impact factor: 5.191

4.  Profiling the Proteome of Mycobacterium tuberculosis during Dormancy and Reactivation.

Authors:  Vipin Gopinath; Sajith Raghunandanan; Roshna Lawrence Gomez; Leny Jose; Arun Surendran; Ranjit Ramachandran; Akhil Raj Pushparajan; Sathish Mundayoor; Abdul Jaleel; Ramakrishnan Ajay Kumar
Journal:  Mol Cell Proteomics       Date:  2015-05-29       Impact factor: 5.911

5.  Deciphering the proteome of the in vivo diagnostic reagent "purified protein derivative" from Mycobacterium tuberculosis.

Authors:  Yun Sang Cho; Karen M Dobos; Jessica Prenni; Hongliang Yang; Ann Hess; Ida Rosenkrands; Peter Andersen; Sung Weon Ryoo; Gill-Han Bai; Michael J Brennan; Angelo Izzo; Helle Bielefeldt-Ohmann; John T Belisle
Journal:  Proteomics       Date:  2012-04       Impact factor: 3.984

6.  Investigating β-Lactam Drug Targets in Mycobacterium tuberculosis Using Chemical Probes.

Authors:  Samantha R Levine; Kimberly E Beatty
Journal:  ACS Infect Dis       Date:  2021-01-20       Impact factor: 5.084

7.  Portrait of a pathogen: the Mycobacterium tuberculosis proteome in vivo.

Authors:  Nicole A Kruh; Jolynn Troudt; Angelo Izzo; Jessica Prenni; Karen M Dobos
Journal:  PLoS One       Date:  2010-11-11       Impact factor: 3.240

Review 8.  Physiology of mycobacteria.

Authors:  Gregory M Cook; Michael Berney; Susanne Gebhard; Matthias Heinemann; Robert A Cox; Olga Danilchanka; Michael Niederweis
Journal:  Adv Microb Physiol       Date:  2009       Impact factor: 3.517

9.  Proteins with complex architecture as potential targets for drug design: a case study of Mycobacterium tuberculosis.

Authors:  Bálint Mészáros; Judit Tóth; Beáta G Vértessy; Zsuzsanna Dosztányi; István Simon
Journal:  PLoS Comput Biol       Date:  2011-07-21       Impact factor: 4.475

10.  Identification of gene targets against dormant phase Mycobacterium tuberculosis infections.

Authors:  Dennis J Murphy; James R Brown
Journal:  BMC Infect Dis       Date:  2007-07-26       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.